Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning

Launched by DAVID WILLIAMS · Oct 12, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for a serious condition called Severe Combined Immunodeficiency, X-Linked (SCID-X1), which affects the immune system and makes it difficult for the body to fight infections. The trial involves giving patients a low dose of a medication called busulfan to prepare their bodies, followed by an infusion of their own specially treated blood cells that have been modified to help their immune system work better. The goal is to see if this approach can safely improve the health of patients with SCID-X1.

To be eligible for the trial, participants must be male and 5 years old or younger, diagnosed with SCID-X1, and without a matching bone marrow donor. They also need to agree to follow-up check-ups for 15 years after treatment. During the trial, participants will be closely monitored for two years after receiving the treatment. This study aims to provide valuable information about how effective and safe this gene therapy is for young boys with SCID-X1, which could lead to better treatments in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • - 1. Diagnosis of SCID-X1 based on immunophenotype and lack of T cell function (proliferation to PHA \<10% of the lower limit of normal for the laboratory) AND confirmed by a mutation in IL2RG 2. Lack of an HLA identical (A, B, C, DR, DQ) related donor 3. Age 5 years old or younger 4. Signed informed consent 5. Documentation of willingness to follow up for 15 years post-infusion as currently required by the FDA 6. If the patient has previously undergone allogeneic transplant, lack of donor T cell engraftment must be documented.
• • 7. Age at least 8 weeks by the time of busulfan administration
• Exclusion Criteria:
• • 1. Patients with an active, therapy-resistant infection. Infections that are known to be highly morbid in SCID patients will be considered active and therapy-resistant if the infectious agent is repeatedly isolated despite a minimum of 2 weeks of appropriate therapy and is associated with significant organ dysfunction (including but not limited to abnormalities listed below).
• • 1. Mechanical ventilation including continuous positive airway pressure
• • 2. Abnormal liver function defined by AST and ALT \>10 times the upper range of normal OR Bilirubin \>2 mg/dL
• • 3. Shortening fraction on echocardiogram \<25% or ejection fraction \<50%
• • 4. Renal failure defined as glomerular filtration rate \<30 ml/min/1.73 m2 or dialysis dependence
• • 2. Uncontrolled seizure disorder
• • 3. Encephalopathy
• • 4. Documented coexistence of any disorder known to affect DNA repair
• • 5. Diagnosis of active malignant disease other than EBV-associated lymphoproliferative disease
• • 6. Patients with evidence of infection with HIV-1
• • 7. Major (life-threatening) congenital anomalies. Examples of "major (life-threatening) congenital anomalies" include, but are not limited to: unrepaired cyanotic heart disease, hypoplastic lungs, anencephaly or other major central nervous system malformations, other severe non-repairable malformations of the gastrointestinal or genitourinary tracts that significantly impair organ function.
• • 8. Other conditions which in the opinion of the P.I. or co-investigators, contra-indicate collection and/or infusion of transduced cells or indicate patient's inability to follow the protocol. These may include for example clinical ineligibility to receive anesthesia, severe deterioriation of clinical condition of the patient after collection of bone marrow but before infusion of transduced cells, or documented refusal or inability of the family to return for scheduled visits. There may be other unforeseen rare circumstances that would result in exclusion of the patient, such as sudden loss of legal guardianship
• • -